VIRAZOLE (ribavirin) by Bausch + Lomb. Approved for nucleoside analog antiviral [epc]. First approved in 1985.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
VIRAZOLE (ribavirin) is a nucleoside analog antiviral administered via inhalation solution for the treatment of severe respiratory syncytial virus (RSV) infections, particularly in immunocompromised patients. It works by inhibiting viral nucleic acid synthesis, disrupting the replication machinery of RNA viruses. This inhaled formulation allows direct delivery to the respiratory tract where RSV infection typically occurs.
As a decades-old inhaled antiviral approaching loss of exclusivity, the brand team is likely lean and focused on retention strategies rather than growth initiatives.
Nucleoside Analog Antiviral
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2
Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Worked on VIRAZOLE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
VIRAZOLE offers minimal career growth opportunity, as evidenced by zero linked job openings and LOE-approaching lifecycle status. Professionals pursuing long-term growth and impact should prioritize higher-velocity assets; this product is suited only for specialized niche roles or as a stable, low-intensity assignment.